The fight against cancer may gain a powerful ally through a deeper understanding of the enzyme family known as APOBECs. Research led by Reuben S. Harris, PhD, at the University of Texas Health Science Center at San Antonio, reveals how these enzymes, which typically protect the body from viral infections, can inadvertently contribute to cancer progression. This discovery could pave the way for new strategies aimed at reducing cancer recurrence after surgical treatment.
APOBECs, or apolipoprotein B mRNA-editing enzymes, play a crucial role in the immune response by mutating viral DNA to prevent infections. However, according to Harris, these same enzymes can malfunction in cancerous cells. “In many instances, APOBECs become dysregulated and instead of destroying viruses, they end up damaging our genomes,” he explained. This paradox highlights how the protective mechanisms of the immune system can sometimes turn against the body, leading to the development of more aggressive tumors.
Harris emphasizes the significance of timing in cancer treatment. “When a tumor that tests positive for APOBEC is surgically removed, we have a crucial opportunity to intervene,” he stated. By inhibiting the activity of these enzymes following surgical resection, there is potential to lower the risk of cancer recurrence or the emergence of medication-resistant variants.
The implications of this research are substantial. “If we can stop the adverse effects of APOBECs, we can significantly reduce the likelihood of cancer returning or spreading,” Harris noted. This proactive approach could transform the standard of care in oncology, particularly for patients with APOBEC-positive tumors.
The collaboration between Texas Public Radio (TPR) and the University of Texas Health Science Center enables ongoing exploration of how scientific advancements in San Antonio impact medical practices globally. As researchers like Harris delve deeper into the complexities of APOBECs, the potential for innovative cancer treatments continues to grow, offering hope to countless patients and their families.
This research, originally presented on April 7, 2024, not only underscores the dual nature of immune enzymes but also illustrates the importance of targeted therapies in the evolving landscape of cancer treatment. By addressing the underlying mechanisms at play, scientists aim to harness the power of the immune system in a way that maximizes its benefits while minimizing harm.
